{"id":811215,"date":"2025-02-10T17:03:42","date_gmt":"2025-02-10T22:03:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/"},"modified":"2025-02-10T17:03:42","modified_gmt":"2025-02-10T22:03:42","slug":"lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/","title":{"rendered":"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement"},"content":{"rendered":"
\n

PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) — <\/strong>LIXTE Biotechnology Holdings, Inc<\/u><\/a>. (\u201cLIXTE\u201d or the \u201cCompany\u201d) (Nasdaq: LIXT<\/u><\/a> and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the \u201cSEC\u201d) of the Company\u2019s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the \u201cRegistration Statement\u201d), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.<\/p>\n

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company\u2019s common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such any state or jurisdiction.<\/p>\n

About LIXTE Biotechnology Holdings, Inc.<\/strong><\/p>\n

LIXTE Biotechnology Holdings, Inc.<\/u><\/a>\u00a0is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity.<\/a>\u00a0Based on extensive published preclinical data, LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE’s new approach has no known competitors and is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are in progress. LB-100 is part of a pioneering effort in an entirely new field of cancer biology \u2013\u00a0activation lethality\u00a0\u2013 that is advancing a new treatment paradigm. Additional information about LIXTE can be found at www.lixte.com<\/u><\/a>.<\/u><\/p>\n

Forward-Looking Statement Disclaimer<\/strong><\/p>\n

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company’s intellectual property worldwide, and the Company\u2019s ability to obtain and maintain compliance with Nasdaq\u2019s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as “intend,” anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology.<\/p>\n

The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.<\/p>\n

Readers are urged to read the risk factors set forth in the Company\u2019s filings with the United States Securities and Exchange Commission at\u00a0https:\/\/www.sec.gov<\/u><\/a>.<\/u> The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

For more information about LIXTE,\u00a0contact: <\/strong>info@lixte.com<\/u><\/a>
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533<\/p>\n

or<\/p>\n

PondelWilkinson Inc.\u00a0Investor Relations
pwinvestor@pondel.com<\/u><\/a>
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962<\/p>\n

\n<\/div>\n

\"\"
\"\"<\/div>\n

\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (\u201cLIXTE\u201d or the \u201cCompany\u201d) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the \u201cSEC\u201d) of the Company\u2019s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the \u201cRegistration Statement\u201d), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement. This press release shall not constitute an offer to sell or … <\/p>\n

Continue reading “LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-811215","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (\u201cLIXTE\u201d or the \u201cCompany\u201d) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the \u201cSEC\u201d) of the Company\u2019s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the \u201cRegistration Statement\u201d), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement. This press release shall not constitute an offer to sell or … Continue reading "LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-10T22:03:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement\",\"datePublished\":\"2025-02-10T22:03:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/\"},\"wordCount\":660,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/\",\"name\":\"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==\",\"datePublished\":\"2025-02-10T22:03:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/","og_locale":"en_US","og_type":"article","og_title":"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - Market Newsdesk","og_description":"PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (\u201cLIXTE\u201d or the \u201cCompany\u201d) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the \u201cSEC\u201d) of the Company\u2019s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the \u201cRegistration Statement\u201d), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement. This press release shall not constitute an offer to sell or … Continue reading \"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-10T22:03:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement","datePublished":"2025-02-10T22:03:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/"},"wordCount":660,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/","name":"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==","datePublished":"2025-02-10T22:03:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NjAzNyM2NzQ0Mzg2IzUwMDAyNTY5NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=811215"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811215\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=811215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=811215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=811215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}